Skip to main content

Table 4 Trial Registration Numbers of Ongoing Trials

From: Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials

Stable Cardiovascular Disease
ACTRN12614000093684 - The LoDoCo2 Trial: A randomised controlled trial on the effect of low dose Colchicine for secondary prevention of cardiovascular disease in patients with established, stable coronary artery disease. This study is not yet recruiting. Sponsor: Heart Research Institute of Western Australia/Aspen Pharmacare Australia. Target enrolment: 3000 patients.
NCT02153983 - Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome. This study is currently recruiting participants. Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Target enrolment: 100 patients.
NCT02162303 - Colchicine in Vascular Inflammation Assessed With PET Imaging (COLPET). This study is currently recruiting participants. Sponsor: Montreal Heart Institute. Target enrolment: 106 patients.
Acute Coronary Syndrome
NCT01906749 - Colchicine for Acute Coronary Syndromes (COACS). This study is currently recruiting participants. Sponsor: Maria Vittoria Hospital. Target enrolment: 500 patients.
NCT01936285 - Colchicine in ST-elevation Myocardial Infarction. This study is currently recruiting participants. Sponsor: G. Gennimatas General Hospital. Target enrolment: 75 patients.
NCT02095522 - COlchicine Improve EnDothElial Function in Non ST Elevation Myocardial Infarction Patients (CODEN). This study is not yet open for participant recruitment. Sponsor: Tel-Aviv Sourasky Medical Center. Target enrolment: 100 patients.
Percutaneous Intervention
NCT01709981 - Anti-inflammatory Effects of Colchicine in PCI. This study is currently recruiting participants. Sponsor: New York University School of Medicine. Target enrolment: 400 patients.
Post-Operative
ISRCTN72835417. COlchicine for the preVention of postopErative atrial fibRillation in patients undergoing Coronary Artery By-pass Grafting (COVER CABG). Completed. Sponsor: Catholic University of the Sacred Heart-Rome (Italy). Target enrolment: 320 patients.
ACTRN12613001345774 - Colchicine for the Primary Prevention of Atrial Fibrillation after Cardiac Surgery: A Double Blind Placebo Randomised Controlled Trial. Recruiting. Sponsor: Barwon Health - The Geelong Hospital. Target enrolment: 520 patients.
NCT01266694 - Cochicine Treatment for Post- Operative Pericardial Effusion (POPE2). This study has been completed. Sponsor: French Cardiology Society. Target enrolment: 199 patients.
NCT01985425 - Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study (COP-AF Pilot) This study is currently recruiting participants. Sponsor: McMaster University. Target enrolment: 100 patients.
NCT02122484 - Colchicine in Coronary Artery Bypass Graft (CABG). This study is ongoing, but not recruiting participants. Sponsor: G.Gennimatas General Hospital. Target enrolment: 75 patients.
NCT02177266 - Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation. This study is not yet open for participant recruitment. Sponsor: Mayo Clinic. Target enrolment: 242 patients.
Chronic Atrial Fibrillation
NCT01755949 - Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation and Post AF Ablation. This study is currently recruiting participants. Sponsor: Mayo Clinic. Target enrolment: 60 patients.